57718-47-5

Basic information

• Product Name: N1-(1-BENZYL-4-PIPERIDYL)BENZENE-1,2-DIAMINE
• Synonyms: BUTTPARK 95\04-30;N1-(1-BENZYL-4-PIPERIDYL)BENZENE-1,2-DIAMINE;N-(1-BENZYL-4-PIPERIDYL)BENZENE-1,2-DIAMINE;N-[1-(phenylmethyl)piperidin-4-yl]benzene-1,2-diamine;N1-(1-Benzyl-4-piperidyl)benzene-1,2-diamine, tech;N-[1-(Phenylmethyl)piperidin-4-yl]-1,2-benzenediamine;4-[(2-Aminophenyl)amino]-1-benzylpiperidine;N-(1-Benzylpiperidin-4-yl)benzene-1,2-diamine, tech
• CAS NO: 57718-47-5
• Molecular Formula: C₁₈H₂₃N₃
• Molecular Weight: 281.4
• EINECS: 260-916-3
• Mol File: 57718-47-5.mol
• Article Data: 5

Chemical Properties

• Melting Point: 111 °C
• Boiling Point: 447.1°Cat760mmHg
• Flash Point: 224.2°C
• Appearance: /
• Density: 1.157g/cm³
• Vapor Pressure: 3.45E-08mmHg at 25°C
• Refractive Index: 1.655
• PKA: 8.16±0.10(Predicted)
• CAS DataBase Reference: N1-(1-BENZYL-4-PIPERIDYL)BENZENE-1,2-DIAMINE(CAS DataBase Reference)
• NIST Chemistry Reference: N1-(1-BENZYL-4-PIPERIDYL)BENZENE-1,2-DIAMINE(57718-47-5)
• EPA Substance Registry System: N1-(1-BENZYL-4-PIPERIDYL)BENZENE-1,2-DIAMINE(57718-47-5)

Safety Data

• Hazard Codes: Xi
• Hazardous Substances Data: 57718-47-5(Hazardous Substances Data)

Usage

Description

N1-(1-BENZYL-4-PIPERIDYL)BENZENE-1,2-DIAMINE is a chemical compound characterized by the presence of two benzene rings and a piperidine ring. It is widely recognized in the field of medicinal chemistry as a versatile building block for the development of potential drug candidates. N1-(1-BENZYL-4-PIPERIDYL)BENZENE-1,2-DIAMINE has demonstrated promising properties in preliminary studies, including its potential as an antihistamine and antipsychotic agent. Additionally, it has been investigated for its possible therapeutic effects in the treatment of Parkinson's disease and other neurodegenerative disorders. However, further research is essential to comprehensively elucidate its pharmacological properties and explore its full range of potential therapeutic applications.

Uses

Used in Pharmaceutical Industry:
N1-(1-BENZYL-4-PIPERIDYL)BENZENE-1,2-DIAMINE is used as a key intermediate in the synthesis of various drug candidates due to its unique chemical structure and potential pharmacological activities.
Used in Antihistamine Development:
N1-(1-BENZYL-4-PIPERIDYL)BENZENE-1,2-DIAMINE is utilized as a precursor in the development of antihistamine agents, aiming to alleviate symptoms associated with allergic reactions.
Used in Antipsychotic Drug Research:
N1-(1-BENZYL-4-PIPERIDYL)BENZENE-1,2-DIAMINE is employed as a starting material in the research and development of antipsychotic drugs, targeting the treatment of mental health disorders such as schizophrenia and bipolar disorder.
Used in Neurodegenerative Disorder Treatment:
N1-(1-BENZYL-4-PIPERIDYL)BENZENE-1,2-DIAMINE is studied for its potential role in the treatment of neurodegenerative disorders, including Parkinson's disease, with the aim of providing therapeutic benefits to patients suffering from these conditions.

InChI:InChI=1/C18H23N3/c19-17-8-4-5-9-18(17)20-16-10-12-21(13-11-16)14-15-6-2-1-3-7-15/h1-9,16,20H,10-14,19H2

Upstream product

• 7255-89-2 (1-Benzyl-piperidin-4-yl)-(2-nitro-phenyl)-amine 
• 3612-20-2 1-phenylmethyl-4-piperidone 
• 95-54-5 1,2-diamino-benzene 
• 50541-93-0 4-amino-1-benzylpiperidine 
• 1493-27-2 ortho-nitrofluorobenzene 

Downstream Products

• 84176-75-0 1-(1-Benzyl-4-piperidinyl)-1H-benzimidazole 
• 301220-17-7 α-(R)-(3-(S)-((4-Benzoimidazol-1-yl-piperidin-1-yl)methyl)4-(S)-phenyl-pyrrolidin-1-yl)-cyclohexaneacetic acid, 4-methoxy-benzyl ester 
• 83763-11-5 1-piperidine-4-yl-1H-benzimidazole 
• 1096357-14-0 C₂₃H₂₇N₃O₂ 

Relevant articles and documents

SUBSTITUTED BENZIMIDAZOLES AS NOCICEPTIN RECEPTOR MODULATORS

The invention provides modulators of the nociceptin receptor (NOP), including both agonists and antagonists. A compound of the invention can be a selective modulator of NOP with respect to the μ- and κ- opioid receptors (MOP and KOP), thus providing a therapeutic method for the treatment of conditions wherein selective NOP modulation is medically indicated and MOP or KOP modulation may be less desirable. A compound of the invention can be a NOP full agonist, partial agonist, inverse agonist, positive or negative allosteric modulator, or a functionally biased agonist. A compound of the invention can be used for the treatment of an anxiety state, post-traumatic stress disorder, addictive disorders (including overuse of alcohol, tobacco, and drugs of abuse such as cocaine, amphetamines, and opitates), misregulated food intake and/or energy expenditure, cough, sleep disorders, migraine, pain, depression, or neurodegenerative disorders such as Parkinsons disease or Alzheimers disease.

From hit to lead. Combining two complementary methods for focused library design. Application to μ opiate ligands

Compound 1 obtained by random screening and displaying a micromolar activity on the μ opiate receptor was chosen as a starting point for optimization. Two complementary concepts of similarity were used for the design of analogues and compared. These are based, respectively, on a computer-aided comparison of pharmacophoric patterns and on topological similarity. The structure-activity relationships are discussed in light of both similarity concepts. Compound 40, an N-methyl-3-(4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]decyl)acetamide derivative, designed by combining the structure-activity relationships enlightened by each method, has a subnanomolar affinity for μ (h) receptor (IC50=0.9 nM). It is a promising lead, allowing the design of a new series of analogues substituted at the N-3 of the spirocycle moiety.

Dipeptides which promote release of growth hormone

Compounds of formula (I) are growth hormone releasing peptide mimetics which are useful for the treatment and prevention of osteoporosis. STR1